60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study

60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study

•This was a randomized, single-blind, cross-over study in Chinese patients.•Ticagrelor exhibits more potent antiplatelet aggregation compared with clopidogrel.•60 mg QD ticagrelor had a stronger inhibitory effect than clopidogrel.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thrombosis research 2020-06, Vol.190, p.60-61
Hauptverfasser: He, Meijiao, Zhang, Yun, Yan, Wei, Liu, Guangzhong, Sun, Danghui, Yuan, Yue, Shi, Jing, Kong, Yihui, Li, Yue
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•This was a randomized, single-blind, cross-over study in Chinese patients.•Ticagrelor exhibits more potent antiplatelet aggregation compared with clopidogrel.•60 mg QD ticagrelor had a stronger inhibitory effect than clopidogrel.
ISSN:0049-3848
1879-2472
DOI:10.1016/j.thromres.2020.03.014